11,220 shares in DexCom, Inc. (NASDAQ:DXCM) bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,220 shares of the medical device company’s stock, valued at approximately $1,395,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Team Hewins LLC boosted its holdings in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after purchasing an additional 83 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares in the last quarter. Capital Insight Partners LLC boosted its holdings in DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after purchasing an additional 90 shares during the last quarter. Gulf International Bank UK Ltd boosted its holdings in DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its holdings in DexCom by 13.1% in the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock valued at $120,000 after purchasing an additional 100 shares during the last quarter. 97.75% of shares are held by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DexCom stock opened at $69.62 on Thursday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market cap of $27.69 billion, a P/E ratio of 44.68, a PEG ratio of 2.16 and a beta of 1.18. The company has a 50-day moving average price of $70.21 and a 200-day moving average price of $103.85. The company has a current ratio of 2.82, a quick ratio of 2.48, and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM – Get Your Free Report ) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. In the same period last year, the company earned $0.34 per share. DexCom’s revenue was up 15.3% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a decrease of 0.00 % in the stock holding. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a decrease of 0.00 % in the stock holding. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in ownership of the shares. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock worth $126,390 over the last three months. Insiders hold 0.30% of the company’s stock.

Analysts on Wall Street are forecasting an increase

Several equities analysts have issued reports on DXCM shares. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Stifel Nicolaus upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Oppenheimer decreased their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Royal Bank of Canada lowered their price objective on shares of DexCom from $130.00 to $120.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Baird RW downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.69, according to MarketBeat.com.

Check out our latest research report on DexCom

About DexCom

(Free report)

DexCom, Inc, a medical device company, focuses on the design, development and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes as well as for use by healthcare providers. Its products include the Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which allows authorized third-party software developers to integrate real-time CGM data into their digital health applications and devices; and the Dexcom ONE, which is designed to replace fingerstick blood glucose testing for diabetes treatment decisions.

Featured stories

Want to see what other hedge funds hold DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for DexCom, Inc. (NASDAQ:DXCM – Free Report).

Get news and reviews for DexCom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.